WithdrawnPhase 4NCT02899702

Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children

Studying Bacterial toxic-shock syndrome

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Hospices Civils de Lyon
Principal Investigator: Etienne JAVOUHEY
Hospices Civils de Lyon
Intervention: PRIVIGEN (CSL Behring)(drug)
Eligibility: 17 years · All sexes
Timeline: 2020 – 2024

Study locations (1)

Hôpital Femme Mère Enfant, Bron, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02899702 on ClinicalTrials.gov

Other trials for Bacterial toxic-shock syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGNCT07199998
Impact of Internal Menstrual Protections on Immunity and Vaginal Microbiota
Centre National de la Recherche Scientifique, France

See all trials for Bacterial toxic-shock syndrome →

← Back to all trials